Summary
This ESMO clinical practice guideline interim update synthesises evidence on first-line systemic therapy for patients with advanced urothelial carcinoma. The guideline, authored by an international panel of specialists, reflects current best practice recommendations as of 2024. The update is intended to support clinicians and multidisciplinary teams in treatment decision-making for this patient population.
UK applicability
As an ESMO guideline with European authorship, the recommendations are directly applicable to UK oncology practice and NHS treatment protocols. The evidence base and therapeutic algorithms should align with UK standard-of-care pathways for advanced urothelial cancer.
Key measures
Treatment response, survival outcomes, and safety profiles of first-line therapeutic agents in advanced urothelial carcinoma (as typical for ESMO clinical practice guidelines)
Outcomes reported
The guideline update addresses first-line therapeutic recommendations for patients with advanced urothelial carcinoma, synthesising evidence on treatment efficacy and safety. As suggested by the title, the update reflects current evidence on systemic therapy options for this cancer type.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.